Anti-MerTK (Tyr749/753/754) Antibody

Our Anti-MerTK (Tyr749/753/754) rabbit polyclonal phosphospecific primary antibody from PhosphoSolutions is produced in-house. It detects human, mouse, and rat MerTK Tyr749/753/754 and is antigen affinity purified from pooled serum. It is great for use in WB.



SKU: p186-749

Volume: 100 µL
Price:
Sale price$430

Product Specific References for Applications and Species

Western Blot: Human
PMID Dilution Publication
376716151:1000Dorion, MF, et al. 2023. MerTK is a mediator of alpha-synuclein fibril uptake by human microglia. Brain, .
34038857 not listed Zheng, H., et al. 2021. UNC5293, a potent, orally available and highly MERTK-selective inhibitor. European Journal of Medicinal Chemistry, 220,p. 113534.
31497954 not listed Da, C., et al. 2019. Data-driven construction of anti-tumor agents with controlled polypharmacology. Journal of the American Chemical Society, 141(39):15700-15709.
30482852 not listed Sinik, L., et al. 2019. . Inhibition of MERTK promotes suppression of tumor growth in BRAF mutant and BRAF wild-type melanoma. Molecular Cancer Therapeutics, 18(2), pp.278-288.
303471555 not listed Zhao, J., et al. 2018. Highly selective MERTK inhibitors achieved by a single methyl group. Journal of Medicinal Chemistry, 61(22), pp.10242-10254.
30194074 not listed Yan, D., et al. 2018. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non–small Cell Lung Cancers Expressing Wild-type EGFR Family Members. Clinical Cancer Research, 24(24), pp.6523-6535.
30093568 not listed McDaniel, N.K., et al. 2018. MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents. Molecular Cancer Therapeutics, 17(11), pp.2297-2308.
29045015 not listed Branchford, B.R., et al. 2018. The small‐molecule MERTK inhibitor UNC 2025 decreases platelet activation and prevents thrombosis. Journal of Thrombosis and Haemostasis, 16(2), pp.352-363.
27783662 not listed Sufit, A., et al. 2016. MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme. PLoS One, 11(10):e0165107.
27649555 not listed DeRyckere, D., et al. 2017. UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models. Clinical Cancer Research, 23(6):1481-1492.
27158668 not listed Minson, K.A., et al. 2016. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight, 1(3):e85630.
26162689 not listed Cummings, C.T., et al. 2015. Small molecule inhibition of MERTK is efficacious in non-smal cell lung cancer models independent of driver oncogene status. Molecular Cancer Therapeutics, 14(9):2014-2022.
25762638 not listed Lee-Sherick, A.B., et al. 2015. Efficacy of a Mer and lt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. Oncotarget, 6(9):6722-36.
25372020 not listed Cummings, C.T., et al. 2015. Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer. Oncotarget, 5(21):10434-45.
24219778 not listed Zhang, W., et al. 2013. Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis. Journal of Medicinal Chemistry, 56(23), pp.9693-9700.
24195762 not listed Zhang, W., et al. 2013. Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors. Journal of Medicinal Chemistry, 56(23), pp.9683-9692.
23997116 not listed Christoph, S., et al. 2013. UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Molecular Cancer Therapeutics, 12(11):2367-77.
23693152 not listed Liu, J., et al. 2013. UNC1062, a new and potent Mer inhibitor. European Journal of Medicinal Chemistry, 65:83-93.
23585477 not listed Schlegel, J., et al. 2013. MERTK receptor tyrosine kinase is a therapeutic target in melanoma. Journal of Clinical Investigation, 123(5):2257-67.
23474756 not listed Lee-Sherick, A.B., et al. 2013. Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia. Oncogene, 32(46):5359-68.
23353780 not listed Brandao, L.N., et al. 2013. Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia. Blood Cancer Journal, 3:e101.
22890323 not listed Linger, R., et al. 2013. Mer or Axl Receptor Tyrosine Kinase Inhibition Promotes Apoptosis, Blocks Growth, and Enhances Chemosensitivity of Human Non-Small Cell Lung Cancer. Oncogene, 32(29):3420-3431.
Western Blot: Mouse
PMID Dilution Publication
303471555 not listed Zhao, J., et al. 2018. Highly selective MERTK inhibitors achieved by a single methyl group. Journal of Medicinal Chemistry, 61(22), pp.10242-10254.
29045015 not listed Branchford,B.R., et al. 2017. The small‐molecule MERTK inhibitor UNC 2025 decreases platelet activation and prevents thrombosis. Journal of Thrombosis and Haemostasis, 16(2), pp.352-363.
25068800 not listed Zhang, W, et al. 2014. UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. Journal of Medicinal Chemistry, 57(16), pp.7031-7041.
24219778 not listed Zhang, W, et al. 2013. Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis. Journal of Medicinal Chemistry, 56(23), pp.9693-9700.
24195762 not listed Zhang, W, et al. 2013. Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors. Journal of Medicinal Chemistry, 56(23), pp.9683-9692.

Bulk Order Anti-MerTK (Tyr749/753/754) Antibody

Product Specific Protocols

Related Products

Recently Viewed